136 related articles for article (PubMed ID: 37130801)
21. Predicting flow cytometry crossmatch results from single-antigen bead testing.
Flynn PA; Fernando S; Worthington JE; Poulton KV
Int J Immunogenet; 2024 Apr; 51(2):93-99. PubMed ID: 38374539
[TBL] [Abstract][Full Text] [Related]
22. HLA graph, a free and ready-to-use bioinformatics tool to explore anti-HLA eplets reactivity pattern.
Usureau C; Jacob V; Dubois V; Masson D; Jollet I; Desoutter J; Taupin JL; Guillaume N
HLA; 2022 Sep; 100(3):244-253. PubMed ID: 35672253
[TBL] [Abstract][Full Text] [Related]
23. The Most Common HLA Alleles and Anti-HLA Antibodies to Know for Virtual Cross-Match.
Baştürk B; Kantaroğlu B; Kavuzlu M; Sarıtürk Ç
Exp Clin Transplant; 2016 Nov; 14(Suppl 3):53-55. PubMed ID: 27805512
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience.
Olszowska-Zaremba N; Gozdowska J; Zagożdżon R
Transpl Immunol; 2022 Oct; 74():101672. PubMed ID: 35868613
[TBL] [Abstract][Full Text] [Related]
25. Utilizing principal component analysis in the identification of clinically relevant changes in patient HLA single antigen bead solid phase testing patterns.
Cornaby C; Weimer ET
PLoS One; 2023; 18(10):e0288743. PubMed ID: 37883384
[TBL] [Abstract][Full Text] [Related]
26. Pre-transplant donor specific anti-HLA antibody is associated with antibody-mediated rejection, progressive graft dysfunction and patient death.
Fidler SJ; Irish AB; Lim W; Ferrari P; Witt CS; Christiansen FT
Transpl Immunol; 2013 Jun; 28(4):148-53. PubMed ID: 23665534
[TBL] [Abstract][Full Text] [Related]
27. Impact of pre-transplant donor specific antibodies detected by Luminex with negative microlymphocytotoxicity assay and flow crossmatch in live-related renal transplant recipients.
Abbas K; Aziz T; Musharaf W; Mubarak M; Zafar MN
Clin Transplant; 2023 May; 37(5):e14935. PubMed ID: 36799009
[TBL] [Abstract][Full Text] [Related]
28. Complement and Non-Complement Binding Anti-HLA Antibodies Are Differentially Detected with Different Antigen Bead Assays in Renal Transplant Recipients.
Ouranos K; Panteli M; Petasis G; Papachristou M; Iosifidou AM; Iosifidou MA; Anastasiou A; Samali M; Stangou M; Theodorou I; Lioulios G; Fylaktou A
J Clin Med; 2023 Dec; 12(24):. PubMed ID: 38137802
[TBL] [Abstract][Full Text] [Related]
29. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM
Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671
[TBL] [Abstract][Full Text] [Related]
30. Interpretation of HLA single antigen bead assays.
Ellis TM
Transplant Rev (Orlando); 2013 Oct; 27(4):108-11. PubMed ID: 23958238
[TBL] [Abstract][Full Text] [Related]
31. Prediction of Complement-Binding Capacity of HLA Antibodies Based on Mean Fluorescence Intensity.
Zhao J; Fu YX; Yang T; Shen ZY; Wu CL
Transplant Proc; 2016; 48(6):2235-40. PubMed ID: 27569975
[TBL] [Abstract][Full Text] [Related]
32. Significance of the intraindividual variability of HLA IgG antibodies in renal disease patients observed with different beadsets monitored with two different secondary antibodies on a Luminex platform.
Ravindranath MH; Filippone EJ; Mahowald G; Callender C; Babu A; Saidman S; Ferrone S
Immunol Res; 2018 Oct; 66(5):584-604. PubMed ID: 30324227
[TBL] [Abstract][Full Text] [Related]
33. Comparison of Sensitivity of Immunocomplex Capture Fluorescence Analysis for Detecting Donor-specific Anti-HLA Class II Antibodies in Kidney Transplant Patients.
Ichimaru N; Takayama T; Hirase H; Hisayama Y; Kawamura M; Nakazawa S; Kato T; Abe T; Kaimori JY; Imamura R; Nonomura N; Takahara S
Transplant Proc; 2018 May; 50(4):1074-1076. PubMed ID: 29731068
[TBL] [Abstract][Full Text] [Related]
34. C3d-binding assay for the detection of complement activating HLA antibodies: A useful tool for allocation to highly sensitised recipients in the post-CDC era?
Wong ZE; Downing J; De Santis D; Halse M; Bruce S; Truong L; Martinez P; D'Orsogna LJ
HLA; 2023 Jul; 102(1):13-27. PubMed ID: 36851856
[TBL] [Abstract][Full Text] [Related]
35. Investigating the relationship between class I HLA-specific immunoglobulin-G subclasses, Pan-IgG single antigen bead assays and complement mediated interference in sera from renal transplant recipients.
Goldsmith P; Lowe D; Wong C; Ridgway D; Howse M; Hammad A; Mehra S; Christmas S; Jones A
Transpl Immunol; 2020 Dec; 63():101332. PubMed ID: 32927096
[TBL] [Abstract][Full Text] [Related]
36. An early evaluation of the HISTO SPOT
Cashin J; Flynn P; Worthington J; Lowe M; Canterbury A; Launhardt K; Crosby I; Sheldon S; Venkateswaran R; Poulton K
Int J Immunogenet; 2022 Oct; 49(5):317-324. PubMed ID: 35989448
[TBL] [Abstract][Full Text] [Related]
37. HLA antibody affinity determination: From HLA-specific monoclonal antibodies to donor HLA specific antibodies (DSA) in patient serum.
Hug MN; Keller S; Marty T; Gygax D; Meinel D; Spies P; Handschin J; Kleiser M; Vazquez N; Linnik J; Buchli R; Claas F; Heidt S; Kramer CSM; Bezstarosti S; Lee JH; Schaub S; Hönger G
HLA; 2023 Sep; 102(3):278-300. PubMed ID: 37191252
[TBL] [Abstract][Full Text] [Related]
38. How can we reduce costs of solid-phase multiplex-bead assays used to determine anti-HLA antibodies?
Kamburova EG; Wisse BW; Joosten I; Allebes WA; van der Meer A; Hilbrands LB; Baas MC; Spierings E; Hack CE; van Reekum FE; van Zuilen AD; Verhaar M; Bots ML; Drop AC; Plaisier L; Seelen MA; Sanders JS; Hepkema BG; Lambeck AJ; Bungener LB; Roozendaal C; Tilanus MG; Vanderlocht J; Voorter CE; Wieten L; van Duijnhoven EM; Gelens M; Christiaans MH; van Ittersum FJ; Nurmohamed A; Lardy NM; Swelsen W; van der Pant KA; van der Weerd NC; Ten Berge IJ; Bemelman FJ; Hoitsma A; van der Boog PJ; de Fijter JW; Betjes MG; Heidt S; Roelen DL; Claas FH; Otten HG
HLA; 2016 Sep; 88(3):110-9. PubMed ID: 27534609
[TBL] [Abstract][Full Text] [Related]
39. C1q-fixing human leukocyte antigen assay in immunized renal patients: correlation between Luminex SAB-C1q and SAB-IgG.
Llorente S; Boix F; Eguia J; López M; Bosch A; Martinez H; Gonzalez MJ; López-Hernández R; Salgado G; Moya-Quiles MR; Campillo JA; García-Alonso AM; Minguela A; Jimeno L; Alvarez-López MR; Muro M
Transplant Proc; 2012 Nov; 44(9):2535-7. PubMed ID: 23146446
[TBL] [Abstract][Full Text] [Related]
40. Anti-HLA Antibodies Testing on Solid Phase: Comparative Evaluation of Different Kit Vendors Through Luminex Technology.
Minucci PB; Resse M; Sabia C; Esposito A; De Iorio G; Napoli C
Exp Clin Transplant; 2017 Dec; 15(6):636-640. PubMed ID: 28585912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
